The market is concerned that weight loss drugs (GLP-1 agonists) will cannibalize sales of MedTech diabetes therapies as it decreases the population with type 2 diabetes. GLP-1 agonists gained FDA approval to treat the diabetic population in 2017; meanwhile, MedTech sales have grown. We anticipate the mass market will not have access to GLP-1 agonists to treat obesity until 2028-2029 at the earliest.
MedTech: Near-term Threat of GLP-1 Agonists is Overblown
Want to learn more? Download the Report.
Gain a comprehensive view of global themes, industries, and companies.
Recent earnings calls point to supply chain improvements...Read more